Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration.
Publication/Presentation Date
2-1-2008
Abstract
PURPOSE: To investigate the safety, tolerability, and bioactivity of intravenous infusions of bevacizumab in patients with choroidal neovascularization (CNV) attributable to causes other than age-related macular degeneration.
DESIGN: Nonrandomized clinical trial.
METHODS: Ten patients with CNV received infusions of 5 mg/kg of bevacizumab. The primary efficacy outcome measure was change in visual acuity (VA; Early Treatment Diabetic Retinopathy Study letters read at 4 meters) at 24 weeks and secondary measures were changes from baseline in excess foveal thickness (center subfield thickness), area of fluorescein leakage, and area of CNV.
RESULTS: Infusions were well tolerated and there were no ocular or systemic adverse events. At baseline, median VA was 25.5 letters read at 4 meters (20/80) and median foveal thickness was 346 mum. At the primary endpoint (24 weeks), median VA was 48.5 letters (20/32), representing four lines of improvement from baseline (P = .005), median foveal thickness was 248 mum representing a 72% reduction in excess foveal thickness (P = .007). Four of nine patients had complete elimination of fluorescein leakage, three had near complete elimination (reductions of 91%, 88%, and 87%), two had modest reductions, and one had no reduction. All patients except one showed a reduction in area of CNV with a median reduction of 43%.
CONCLUSIONS: Despite the small number of patients studied, the marked improvement in VA accompanied by prominent reductions in foveal thickness, fluorescein leakage, and area of CNV suggest a beneficial effect. It may be worthwhile to consider further evaluation of systemic bevacizumab in young patients with CNV.
Volume
145
Issue
2
First Page
257
Last Page
266
ISSN
0002-9394
Published In/Presented At
Nguyen, Q. D., Shah, S. M., Hafiz, G., Do, D. V., Haller, J. A., Pili, R., Zimmer-Galler, I. E., Janjua, K., Symons, R. C., & Campochiaro, P. A. (2008). Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration. American journal of ophthalmology, 145(2), 257–266. https://doi.org/10.1016/j.ajo.2007.09.025
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
18054887
Department(s)
Administration and Leadership
Document Type
Article